Drug intelligence / Profile preview

RenuDermCell

Development stage: Unknown
Lead developer: Cell Tech Pharmed
Modality: Cell Therapies
Administration: Intradermal

Overview

RenuDermCell is an autologous dermal fibroblast cell therapy developed by Cell Tech Pharmed in collaboration with the Royan Institute and Barakat Pharmaceutical Group. It consists of cultured autologous human dermal fibroblasts isolated from a patient's post-auricular skin biopsy, which are expanded ex vivo and then administered via intradermal injection. RenuDermCell is approved in Iran for the treatment of facial wrinkles, acne scars, and atrophic skin lesions following skin trauma. The therapy works by replenishing the dermal fibroblast population, which in turn synthesizes extracellular matrix components, primarily collagen, to restore skin structure and elasticity.

Brand names: RenuDermCell
Other names: RenuDermcellautologous dermal fibroblastscultured autologous human fibroblast cells

Beyond the preview

Go deeper on RenuDermCell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenuDermCell.

Explore the full profile